GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines...
Deals this Week: N4 Pharma, Segulah Venture, Allergan
UK-based pharmaceutical company N4 Pharma has issued 1.5 million ordinary shares priced at £0.085 ($0.12) a share in a private placement to raise gross proceeds of £0.012m ($0.016m).
BenevolentAI buys research facility to support drug development
British artificial intelligence (AI) company BenevolentAI has purchased a drug discovery and development facility located on the Babraham Research Campus in Cambridge, UK, to bolster its AI-enabled development of medicines.
Gilead led the global infectious diseases space in 2017
GlobalData projects the total revenue from branded infectious diseases (ID) drugs and vaccines to surpass $75bn in 2017.
Phase I Study of Bromodomain Inhibitor OTX015
This white paper describes the methods and findings of a dose-escalation, open-label, pharmacokinetic, Phase I study of bromodomain inhibitor OTX015 in patients with lymphoma or multiple myeloma.
Reliability and Maintenance Services is Hiring a New Calibration Technician / Engineer
If you are looking to develop your career within an accredited calibration laboratory, a new opportunity has arisen to join Reliability and Maintenance Services’ accredited calibration laboratory team as a calibration technician, reporting to a technical manager.
The ophthalmology biosimilars market is still in its infancy
2017 has proved to be a remarkable year for biosimilars in ophthalmology, with the EMA approval of Amgen’s Amgevita in March 2017, followed by Biogen/Samsung Bioepis’s Imraldi in August and BI’s Cyltezo in November.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.